Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10147283 | 1.00 | PIK3CD (0.34) | PIK3CDLMNACYP2C9DPP4DPP8 | |
| SCHEMBL21964478 | 1.00 | PIK3CD (0.34) | PIK3CDLMNACYP2C9DPP4DPP8 | |
| SCHEMBL17660661 | 1.00 | PIK3CD (0.34) | PIK3CDLMNACYP2C9DPP4DPP8 | |
| SCHEMBL20363145 | 1.00 | PIK3CD (0.34) | PIK3CDLMNACYP2C9DPP4DPP8 | |
| SCHEMBL17660673 | 1.00 | PIK3CD (0.34) | PIK3CDLMNACYP2C9DPP4DPP8 | |
| SCHEMBL16480495 | 1.00 | PIK3CD (0.34) | PIK3CDLMNACYP2C9DPP4DPP8 | |
| SCHEMBL23169001 | 0.82 | PIK3CD (0.32) | PIK3CD | |
| SCHEMBL25761652 | 0.79 | PHGDH (0.32) | LMNACYP2C9 | |
| SCHEMBL24086860 | 0.79 | MAPT (0.37) | — | |
| SCHEMBL20457822 | 0.79 | PIK3CD (0.31) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | PIK3CD 999/4885LMNA 4696/4885CYP2C9 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.